| Missouri Breaks Industries Research | |
| 118 S Willow St, Eagle Butte, South Dakota 57625 | |
| (605) 964-3418 |
| Name | Missouri Breaks Industries Research |
|---|---|
| Organization Name | Missouri Breaks Industries Research, Inc. |
| Location | 118 S Willow St, Eagle Butte, South Dakota 57625 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (605) 964-3418 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The International Association for Dental Research (IADR), with Unilever, today announced the creation of the "IADR Unilever Social Entrepreneur Approach to Change Oral Health Behavior Research Award." This is an IADR award with funding provided exclusively by Unilever.
HIV infected children in South Africa who were exposed to the drug nevirapine at birth (used to help prevent mother to child HIV transmission) and then received a protease inhibitor (PI) for viral suppression achieved lower rates of viremia (virus in the blood stream) if they were switched to nevirapine, compared to children who continued on the PI-based regimen, according to a study in the September 8 issue of JAMA.
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest plans to file for marketing approval in the European Union (EU) for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.
COVID-19 has a big impact on our daily lives and has changed the landscape of the medical and pharmaceutical industries.
› Verified 1 days ago
| NPI Number | 1699754143 |
| Organization Name | MISSOURI BREAKS INDUSTRIES RESEARCH, INC. |
| Doing Business As | MISSOURI BREAKS DURABLE MEDICAL EQUIPMENT |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 118 S Willow St, Eagle Butte, SD 57625 |
| Phone Number | 605-964-3418 |
News Archive
The International Association for Dental Research (IADR), with Unilever, today announced the creation of the "IADR Unilever Social Entrepreneur Approach to Change Oral Health Behavior Research Award." This is an IADR award with funding provided exclusively by Unilever.
HIV infected children in South Africa who were exposed to the drug nevirapine at birth (used to help prevent mother to child HIV transmission) and then received a protease inhibitor (PI) for viral suppression achieved lower rates of viremia (virus in the blood stream) if they were switched to nevirapine, compared to children who continued on the PI-based regimen, according to a study in the September 8 issue of JAMA.
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest plans to file for marketing approval in the European Union (EU) for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.
COVID-19 has a big impact on our daily lives and has changed the landscape of the medical and pharmaceutical industries.
› Verified 1 days ago
News Archive
The International Association for Dental Research (IADR), with Unilever, today announced the creation of the "IADR Unilever Social Entrepreneur Approach to Change Oral Health Behavior Research Award." This is an IADR award with funding provided exclusively by Unilever.
HIV infected children in South Africa who were exposed to the drug nevirapine at birth (used to help prevent mother to child HIV transmission) and then received a protease inhibitor (PI) for viral suppression achieved lower rates of viremia (virus in the blood stream) if they were switched to nevirapine, compared to children who continued on the PI-based regimen, according to a study in the September 8 issue of JAMA.
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest plans to file for marketing approval in the European Union (EU) for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.
COVID-19 has a big impact on our daily lives and has changed the landscape of the medical and pharmaceutical industries.
› Verified 1 days ago
Missouri Breaks Industries Research Type: Durable Medical Equipment & Medical Supplies Supplier Location: 118 S Willow St, Eagle Butte, South Dakota 57625 Phone: (605) 964-3418 |